PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34959222-7	2021	FFAs significantly promoted ROS production and increased the expression of ERK, p38 and JNK, and treatment of the inhibitors of NAPDH oxidase (DPI), p38 (SB202190), ERK1/2 (U0126) and JNK (SP600125) inhibited FAAs-induced NETs production.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	154-162	mitogen-activated protein kinase 1	Homo sapiens	149-152	
28393288-3	2017	In this study, we tested the effect of two highly specific and potent inhibitors of p38 MAPK (namely, SB203580 and SB202190) on human breast cancer cell line MDA-MB-231 to elucidate the controversial role of p38 MAPK on cell proliferation and/or cell migration/metastasis further.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	115-123	mitogen-activated protein kinase 1	Homo sapiens	84-87	
35294968-9	2022	Pre-treatment with selective inhibitors of p38 and Erk1/2 pathways (SB202190 and PD98059) reversed OGD effects on the expression of Ambra1 and Beclin1, suggesting that these pathways induced oxidative stress-mediated autophagy.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	68-76	mitogen-activated protein kinase 1	Homo sapiens	43-46	
32104150-10	2020	U0126 (inhibiting p-ERK1/2) and SB202190 (inhibiting p38) decreased the contents of MCP-1, sICAM-1, and sVCAM-1, but SP600125 (inhibiting p-JNK1/2) had none of these effects.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	32-40	mitogen-activated protein kinase 1	Homo sapiens	53-56	
28801998-12	2017	The p38 MAPK pathway inhibitor SB202190 significantly inhibited the proliferation of HMCs caused by overexpression of RELM-beta.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	31-39	mitogen-activated protein kinase 1	Homo sapiens	4-7	
29577978-10	2018	ERK1/2 inhibition by UO126 caused a decrease in Smad2L phosphorylation while the p38 inhibitor SB202190 and JNK inhibitor SP600125 did not.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	95-103	mitogen-activated protein kinase 1	Homo sapiens	81-84	
29466417-10	2018	Treatment with indomethacin, PP2, SB202190, and PD98059, respective inhibitors of COX enzymes, Src, p38MAPK, and ERK completely abrogated the effect of epinephrine.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	34-42	mitogen-activated protein kinase 1	Homo sapiens	113-116	
29118901-8	2017	Furthermore, the anti-proliferative effect of BBR on HUVECs was effectively abrogated by a PI3K inhibitor LY294002, an ERK1/2 inhibitor PD98059 and a p38 inhibitor SB202190 partly through the restoration of phosphorylation of Akt, ERK1/2 and p38MAPK.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	164-172	mitogen-activated protein kinase 1	Homo sapiens	150-153	
28393288-10	2017	However, interestingly it was observed that a low and noncytotoxic dose of 5 microM of SB203580 and SB202190 also did cause significant cell migration inhibition at 48 h of the treatment, corroborating the fact that p38 MAPK pathway has a critical role in cell migration/metastasis.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	100-108	mitogen-activated protein kinase 1	Homo sapiens	216-219	
26861294-7	2016	The inhibition of p38 MAPK activity by the specific inhibitor SB202190 resulted in inhibition of MAPKAPK-2 activation and noticeable activation of ERK pathway members after SA treatment but in no significant effect on cell viability.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	62-70	mitogen-activated protein kinase 1	Homo sapiens	22-26	
28537766-8	2017	The p38 inhibitor (SB202190) decreased the G1-blocking effect of pirfenidone.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	19-27	mitogen-activated protein kinase 1	Homo sapiens	4-7	
28314481-11	2017	Moreover, MAPK inhibitors including U0126 (an ERK1/2/MAPK inhibitor) and SB202190 (p38/MAPK inhibitor) suppressed an increase of MDR1 mRNA levels in the cells treated with benzophenones (GK, OC) and xanthone ISO, respectively.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	73-81	mitogen-activated protein kinase 1	Homo sapiens	83-86	
26861294-7	2016	The inhibition of p38 MAPK activity by the specific inhibitor SB202190 resulted in inhibition of MAPKAPK-2 activation and noticeable activation of ERK pathway members after SA treatment but in no significant effect on cell viability.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	62-70	mitogen-activated protein kinase 1	Homo sapiens	147-150	
24874889-5	2014	Co-treatment of SB202190 (p38 MAPK inhibitor) and catalytically inactive PLA2 increased ERK phosphorylation, ADAM17 maturation and sTNF-alpha production.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	16-24	mitogen-activated protein kinase 1	Homo sapiens	88-91	
25998312-6	2015	Additionally, the inhibition of the phosphorylation of p38 MAPK by SB202190 protected MG63 cells from Cd-induced apoptosis.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	67-75	mitogen-activated protein kinase 1	Homo sapiens	55-58	
25530682-6	2014	The addition of the p38 MAPK inhibitor SB202190 significantly decreased IL-6 and TNF-alpha production upon LPS or LTA stimulation.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	39-47	mitogen-activated protein kinase 1	Homo sapiens	20-23	
20405237-6	2010	Pretreatment with SB202190, the specific inhibitor of p38, abolished the expression of COX-2 induced by LPS.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	18-26	mitogen-activated protein kinase 1	Homo sapiens	54-57	
23784034-10	2013	Following pre-treatment with the JNK inhibitor II (10 micromol/l), the p38 inhibitor SB202190 (10 micromol/l) or the ERK inhibitor U0126 (10 micromol/l) for 30 min, BEAS-2B cells were exposed to HCl for 30 min.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	85-93	mitogen-activated protein kinase 1	Homo sapiens	71-74	
20506406-5	2010	p38 MAPK activation suppression by SB202190 (p38 MAPK inhibitor) abolished posttranscriptional up-regulation of ADAM17 in PLA(2)-treated cells, while treatment with U0126 (MEK1 and MEK2 inhibitor) increased ADAM17 maturation in SK-N-SH cells.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	35-43	mitogen-activated protein kinase 1	Homo sapiens	4-8	
22490436-5	2012	Inhibition of p38 with SB202190 or JNK with SP600125 attenuated CPT-induced cell death.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	23-31	mitogen-activated protein kinase 1	Homo sapiens	14-17	
22074828-9	2011	SB202190, an inhibitor of p38 MAPK, also inhibited the HG-induced enrichment of ICAM-1.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	0-8	mitogen-activated protein kinase 1	Homo sapiens	26-29	
21853067-1	2011	SB202190, a widely used inhibitor of p38 MAPKalpha and beta, was recently described to induce autophagic vacuoles and cell death in colon and ovarian cancer cells lines and, therefore, this effect was supposed to be specific for transformed cells and to open therapeutic options.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	0-8	mitogen-activated protein kinase 1	Homo sapiens	37-40	
21853067-5	2011	In line with these results, expression of a SB202190-resistant mutant of p38alpha, which significantly increases activity of the p38 pathway under inhibitory conditions, does not block SB202190-dependent vacuole formation, indicating that lack of p38alpha activity is not necessary for this effect.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	44-52	mitogen-activated protein kinase 1	Homo sapiens	73-76	
19652200-8	2009	The ERK1/2 inhibitor PD98059 blocked the effect of thrombin on OSM production in MDMs, whereas the p38 inhibitor SB202190 had no effect.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	113-121	mitogen-activated protein kinase 1	Homo sapiens	99-102	
20419833-12	2010	Inhibition of p38 by SB202190 slightly but significantly diminished the antiproliferative effect of TSA in BxPC-3 cells.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	21-29	mitogen-activated protein kinase 1	Homo sapiens	14-17	
20067818-6	2010	Treatment of cells with the p38 inhibitor SB202190, but not the ERK1/2 inhibitor PD98059, partially reversed BrO(3)(-)-induced G2/M arrest and decreased BrO(3)(-)-induced p-p53, p21 and cyclin B1 expression.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	42-50	mitogen-activated protein kinase 1	Homo sapiens	28-31	
19180563-6	2009	Block of p38 MAPK by SB202190 abolished PLA(2)-induced Fas/FasL upregulation and ERK inactivation, but not ROS generation.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	21-29	mitogen-activated protein kinase 1	Homo sapiens	81-84	
17671214-5	2007	On the other hand, pharmacologic inhibition of p38 MAPK activation in PC-3 or LNCaP cells (SB202190) and ERK1/2 activation in LNCaP cells (PD98059) did not protect against guggulsterone-induced cell death.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	91-99	mitogen-activated protein kinase 1	Homo sapiens	47-50	
17996917-4	2008	The ERK1/2-inhibitor PD98059, the p38-inhibitor SB202190 and the JNK1/2-inhibitor SP600125 partially inhibited the fluoride-induced IL-8 response.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	48-56	mitogen-activated protein kinase 1	Homo sapiens	34-37	
18588859-6	2008	ERK5 activation by either TGF-beta or epidermal growth factor (EGF) was also inhibited by the p38 MAP kinase inhibitor, SB-202190.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	120-129	mitogen-activated protein kinase 1	Homo sapiens	94-97	
18074350-7	2008	Consistent with this, p38 MAPK inhibitors such as SB203580 and SB202190 also synergistically enhance the cytotoxicity of CA4 in cells where p38 MAPK is activated by CA4.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	63-71	mitogen-activated protein kinase 1	Homo sapiens	22-25	
18074350-7	2008	Consistent with this, p38 MAPK inhibitors such as SB203580 and SB202190 also synergistically enhance the cytotoxicity of CA4 in cells where p38 MAPK is activated by CA4.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	63-71	mitogen-activated protein kinase 1	Homo sapiens	140-143	
18285354-7	2008	Pre-treatment with the MAPK inhibitors SP600125 (JNK inhibitor), SB202190 (p38 inhibitor) or PD98059 (ERK inhibitor) significantly inhibited AGE-BSA induction of COX-2 expression and production of PGE(2).	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	65-73	mitogen-activated protein kinase 1	Homo sapiens	23-27	
17617469-11	2007	Among the MAPK inhibitors examined, the p38 MAPK inhibitor, SB202190, significantly suppressed LPS-induced cytokine and PG production.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	60-68	mitogen-activated protein kinase 1	Homo sapiens	40-43	
17617469-12	2007	SB202190 most profoundly suppressed the TNFalpha to IL-10 ratio, demonstrating that p38 MAPK inhibitor reduced predominantly TNFalpha other than IL-10 production.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	0-8	mitogen-activated protein kinase 1	Homo sapiens	84-87	
17457195-9	2007	SB202190 and PD98059 significantly suppressed hyperosmolarity-induced JNK/ERK activation and ISOL-positive cells.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	0-8	mitogen-activated protein kinase 1	Homo sapiens	74-77	
17433832-8	2007	Co-incubation with U0126, SP600125 and SB202190 significantly suppressed LPS-stimulated activation of ERK 1/2, JNK, and p38 MAPK, respectively.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	39-47	mitogen-activated protein kinase 1	Homo sapiens	120-123	
17482227-8	2007	Pretreatment with SB-202190 or SB-203580, inhibitors of the p38 MAP kinase pathway, prevented the 2244-TCB-mediated induction of COX-2 and phosphorylation of p38 and ERK MAP kinases.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	18-27	mitogen-activated protein kinase 1	Homo sapiens	166-169	
17464174-4	2007	The mRNA and surface protein up-regulation of CCR1 and CCR2 in 9CRA-stimulated cells were weakly blocked by the pretreatment of SB202190, a p38 MAPK inhibitor, and PD98059, an upstream ERK inhibitor.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	128-136	mitogen-activated protein kinase 1	Homo sapiens	140-143	
17464174-4	2007	The mRNA and surface protein up-regulation of CCR1 and CCR2 in 9CRA-stimulated cells were weakly blocked by the pretreatment of SB202190, a p38 MAPK inhibitor, and PD98059, an upstream ERK inhibitor.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	128-136	mitogen-activated protein kinase 1	Homo sapiens	185-188	
17202844-8	2006	Furthermore, pretreatment with specific MAPK pathway inhibitors, including the MEK inhibitor U0126, the JNK inhibitor SP600125, and the p38 kinase inhibitor SB202190, completely inhibited ANX-inducible expression of Egr-1.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	157-165	mitogen-activated protein kinase 1	Homo sapiens	136-139	
17543571-11	2007	Interestingly, inhibition of p38 MAPK pathway by SB202190 impeded GTP-mediated caspases activation and differentiation in K562 cells, suggesting that p38 MAPK may act upstream of caspases in our system.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	49-57	mitogen-activated protein kinase 1	Homo sapiens	29-32	
17543571-11	2007	Interestingly, inhibition of p38 MAPK pathway by SB202190 impeded GTP-mediated caspases activation and differentiation in K562 cells, suggesting that p38 MAPK may act upstream of caspases in our system.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	49-57	mitogen-activated protein kinase 1	Homo sapiens	150-153	
16475830-5	2006	Treatment with SB202190 (p38 MAP kinase inhibitor) alone significantly increased apoAI promoter activity; however, in the presence of TNF alpha, apoAI promoter activity was suppressed to an extent similar to that in cells not treated with SB202190.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	15-23	mitogen-activated protein kinase 1	Homo sapiens	25-28	
16672323-12	2006	However, when a series of p38 MAPK and JNK inhibitors were used, only SB202190, also a dual inhibitor, completely suppressed GW7845-induced apoptosis.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	70-78	mitogen-activated protein kinase 1	Homo sapiens	26-29	
16963169-6	2006	The p38 inhibitor SB202190 increased the silica-induced ERK1/2 phosphorylation suggesting that p38 activity may attenuate activation of ERK1/2.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	18-26	mitogen-activated protein kinase 1	Homo sapiens	4-7	
16963169-6	2006	The p38 inhibitor SB202190 increased the silica-induced ERK1/2 phosphorylation suggesting that p38 activity may attenuate activation of ERK1/2.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	18-26	mitogen-activated protein kinase 1	Homo sapiens	95-98	
16202406-11	2006	SB202190, PD98059 and doxycycline markedly suppressed the levels of p-JNK-1/p-JNK-2 and/or p-ERK1/p-ERK2, as well as IL-1beta, TNF-alpha and IL-8 mRNAs and proteins stimulated by hyperosmolar media.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	0-8	mitogen-activated protein kinase 1	Homo sapiens	100-104	
16186797-2	2006	We show here that cotreatment of K562 cells with PMA and low doses of SB202190 (SB), an inhibitor of the p38 MAPK pathway, induced a majority of cells to differentiate towards the megakaryocytic lineage.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	70-78	mitogen-activated protein kinase 1	Homo sapiens	105-108	
16186797-2	2006	We show here that cotreatment of K562 cells with PMA and low doses of SB202190 (SB), an inhibitor of the p38 MAPK pathway, induced a majority of cells to differentiate towards the megakaryocytic lineage.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	70-72	mitogen-activated protein kinase 1	Homo sapiens	105-108	
16497166-8	2006	In contrast, blockage of p38 kinase activity by addition of SB203580 or SB202190, as well as inhibition of c-Jun N-terminal kinase (JNK) using L-JNK-I1, clearly augmented MMP-9 expression and secretion by an upregulation of ERK1/2 phosphorylation.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	72-80	mitogen-activated protein kinase 1	Homo sapiens	25-28	
15833272-10	2005	Pretreating the cells with SB202190, a specific inhibitor of p38, resulted in an increase in basal phosphorylation of ERK1/2 and a subsequent increase in basal serine phosphorylation of STAT-3.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	27-35	mitogen-activated protein kinase 1	Homo sapiens	61-64	
15256218-4	2004	However, the p38 inhibitor SB202190 only slightly protected Molt4 cells from NO toxicity.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	27-35	mitogen-activated protein kinase 1	Homo sapiens	13-16	
15075366-9	2004	Second, the p38 inhibitors SB202190 and SB203580 reduced nucleotide-induced blebbing and actin reorganization, whereas the MAPK kinase-1/2 inhibitor U0126, which blocks ERK1/ERK2 activation, had no discernable effect.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	27-35	mitogen-activated protein kinase 1	Homo sapiens	12-15	
15489211-4	2004	The p38 MAPK inhibitor SB202190 attenuated the MSeA-induced morphological changes and decreased DNA fragmentation and the cleavage of procaspase-3 and PARP in concordant proportions.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	23-31	mitogen-activated protein kinase 1	Homo sapiens	4-7	
14722101-10	2004	The involvement of ERK1/2 and p38 MAP kinase in acetaldehyde-induced apoptosis was confirmed by selective kinase inhibitors U0126, SB203580, and SB202190.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	145-153	mitogen-activated protein kinase 1	Homo sapiens	30-33	
14977049-6	2004	Incubation of cells with the MEK1/2 inhibitor U0126 or the p38 inhibitor SB202190 abolished the UVA and UVB mediated induction of MMP-1 and MMP-10.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	73-81	mitogen-activated protein kinase 1	Homo sapiens	59-62	
15100728-3	2004	RESULTS: ANG II promoted podocyte apoptosis in a time- and dose-dependent manner; ANG II stimulated p38MAPK, but inhibited JNK; SB202190 inhibited both ANG II-induced podocyte apoptosis and p38MAPK phosphorylation; Inhibition of ERK by PD98059 had no effect on ANG II-induced cell apoptosis.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	128-136	mitogen-activated protein kinase 1	Homo sapiens	229-232	
12450322-10	2002	ANG II significantly increased aldosterone release, and this effect was inhibited by the LO inhibitor baicalein, as well as a specific p38 MAPK inhibitor, SB202190, but not by PD098059, a specific inhibitor of the ERK activator MEK.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	155-163	mitogen-activated protein kinase 1	Homo sapiens	135-138	
14596794-11	2003	Inhibition of p38 MAP kinase pathway by SB202190 also blocked LPC-induced expression of IL-8 and RANTES.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	40-48	mitogen-activated protein kinase 1	Homo sapiens	14-17	
12730964-9	2003	SB202190 and U0126, inhibitors of p38 MAPK and ERK1/2 activation, respectively, inhibit IL-1beta and OSM upregulation of COX-2 and PGE(2), indicating that these MAPK cascades are utilized by both stimuli.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	0-8	mitogen-activated protein kinase 1	Homo sapiens	34-37	
12726921-5	2003	PD98059, an inhibitor of ERK, and SB202190, an inhibitor of p38, inhibited vanadate-induced cell growth arrest, upregulation of p21 and cdc2, and degradation of cdc25C.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	34-42	mitogen-activated protein kinase 1	Homo sapiens	60-63	
12605455-5	2003	In addition, they showed that PD98059 and SB202190, synthetic inhibitors of ERK1/ERK2 and p38 respectively, prevented the changes in the rate of neurite elongation induced by agrin in cultured hippocampal neurons.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	42-50	mitogen-activated protein kinase 1	Homo sapiens	81-85	
12605455-5	2003	In addition, they showed that PD98059 and SB202190, synthetic inhibitors of ERK1/ERK2 and p38 respectively, prevented the changes in the rate of neurite elongation induced by agrin in cultured hippocampal neurons.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	42-50	mitogen-activated protein kinase 1	Homo sapiens	90-93	
12226098-8	2002	Interference with p38 MAPK by either the specific inhibitor (SB202190), or a dominant-negative mutant profoundly suppressed the activation of the shrinkage-induced NSC channels.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	61-69	mitogen-activated protein kinase 1	Homo sapiens	18-21	
12450322-10	2002	ANG II significantly increased aldosterone release, and this effect was inhibited by the LO inhibitor baicalein, as well as a specific p38 MAPK inhibitor, SB202190, but not by PD098059, a specific inhibitor of the ERK activator MEK.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	155-163	mitogen-activated protein kinase 1	Homo sapiens	214-217	
12197778-12	2002	However, pretreatment with 10 microM SB202190 or SB203580 (putative p38 inhibitors) attenuated the stimulation of proliferation by S-1-P.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	37-45	mitogen-activated protein kinase 1	Homo sapiens	68-71	
12095140-6	2002	Mitogen-activated protein kinase (MAPK) activity was determined using functional kinase assays and was inhibited with the compounds SB202190 and PD98059.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	132-140	mitogen-activated protein kinase 1	Homo sapiens	34-38	
12097262-7	2002	Even though the PEITC-induced activation of p38 protein kinase was abrogated in the presence of its specific inhibitor SB202190, inhibition of p38 protein kinase activation did not prevent PEITC-induced apoptosis.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	119-127	mitogen-activated protein kinase 1	Homo sapiens	44-47	
12197778-14	2002	Ten to twenty micromolars of SB202190 and SB203580 also dose-dependently ablated the effects of 5 microM S-1-P on heat shock protein 27 accumulation, a downstream consequence of p38 MAPK activation.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	29-37	mitogen-activated protein kinase 1	Homo sapiens	178-181	
12197778-14	2002	Ten to twenty micromolars of SB202190 and SB203580 also dose-dependently ablated the effects of 5 microM S-1-P on heat shock protein 27 accumulation, a downstream consequence of p38 MAPK activation.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	29-37	mitogen-activated protein kinase 1	Homo sapiens	182-186	
11536048-7	2001	Furthermore, KGF was more efficient than FGF1 and FGF2 in inducing actin stress fibres, and the specific p38 inhibitor SB202190 completely abolished this in a dose-dependent manner.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	119-127	mitogen-activated protein kinase 1	Homo sapiens	105-108	
11559033-7	2001	Co-treatment early-G(2) cells with Cd and SB202190, an inhibitor of p38 MAPK, significantly decreased the induction of micronucleus, mitotic arrest, and apoptosis.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	42-50	mitogen-activated protein kinase 1	Homo sapiens	68-71	
11245472-5	2001	Stable expression of a dominant negative mutant of ERK2 or p38 kinase or their respective inhibitor, PD98059 or SB202190, repressed the phosphorylation of p53 at serine 15.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	112-120	mitogen-activated protein kinase 1	Homo sapiens	51-55	
11428868-5	2001	The induced IL-8 and MCP-1 mRNA and proteins were partially suppressed by U0126, a specific MEK inhibitor, and by SB202190, a selective p38 inhibitor.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	114-122	mitogen-activated protein kinase 1	Homo sapiens	136-139	
11439356-4	2001	In addition, treating the cells with p38 inhibitor SB202190 or MEK inhibitor PD98059 specifically inhibited UVB induced p38 or ERK activation, respectively.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	51-59	mitogen-activated protein kinase 1	Homo sapiens	127-130	
11306564-6	2001	Furthermore, PD98059 and SB202190, specific inhibitors of ERK or p38 MAPK respectively, efficiently suppressed CT(105)-induced effects whereas only PD98059 was effective at reducing Abeta-induced effects.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	25-33	mitogen-activated protein kinase 1	Homo sapiens	58-61	
11678615-13	2001	SB202190, an inhibitor of p38, decreased the cytotoxicity and apoptosis induced by high Cd doses.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	0-8	mitogen-activated protein kinase 1	Homo sapiens	26-29	
11294978-7	2001	SB202190 also inhibited apoptosis by almost 40% when ERK activity was reduced in the presence of PD98059.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	0-8	mitogen-activated protein kinase 1	Homo sapiens	53-56	
11154209-8	2001	Furthermore, MCP-1-mediated chemotaxis and transendothelial migration were significantly diminished by a high concentration of SB202190, a broad SAPK inhibitor, or by SB203580, a specific inhibitor of SAPK2/p38, and abolished by pertussis toxin treatment.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	127-135	mitogen-activated protein kinase 1	Homo sapiens	207-210	
9827991-7	1998	The single residue change Q105A in ERK2 enhances the binding of SB202190 at least 25,000-fold compared to wild-type ERK2.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	64-72	mitogen-activated protein kinase 1	Homo sapiens	35-39	
10922992-8	2000	The inhibition of p38 with SB202190 abrogated the osmotic and LPS-induced COX-2 expression and PGI(2) production.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	27-35	mitogen-activated protein kinase 1	Homo sapiens	18-21	
10874022-9	2000	In contrast, SB202190, an inhibitor of p38, decreased the cytotoxicity and apoptosis induced by high Cd doses.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	13-21	mitogen-activated protein kinase 1	Homo sapiens	39-42	
10491322-6	1999	SB202190, an inhibitor of p38, suppressed Erk phosphorylation to the basal level and partially reduced the activation of caspase 3-like proteases and also the cell death.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	0-8	mitogen-activated protein kinase 1	Homo sapiens	42-45	
11123200-6	2001	p38 Inhibition (10 microM SB-202190) did not.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	26-35	mitogen-activated protein kinase 1	Homo sapiens	0-3	
11134248-10	2001	The p38-MAPK inhibitor (SB202190) and the ERK inhibitor (PD98059) diminished PR3-ANCA-mediated superoxide production dose dependently (11.6 +/- 1.7 nmol O(2)(-) to 1.9 +/- 0.6 with 50 microM SB202190 and 4.0 +/- 0.6 with 50 microM PD098059, respectively).	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	191-199	mitogen-activated protein kinase 1	Homo sapiens	42-45	
9827991-7	1998	The single residue change Q105A in ERK2 enhances the binding of SB202190 at least 25,000-fold compared to wild-type ERK2.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	64-72	mitogen-activated protein kinase 1	Homo sapiens	116-120	
9657968-6	1998	Inhibition of the p38 kinase activity with p38-specific inhibitors SB202190 and SB203580 had no effect on cell survival.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	67-75	mitogen-activated protein kinase 1	Homo sapiens	18-21	
9657968-6	1998	Inhibition of the p38 kinase activity with p38-specific inhibitors SB202190 and SB203580 had no effect on cell survival.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	67-75	mitogen-activated protein kinase 1	Homo sapiens	43-46	
9624172-7	1998	In contrast, SB202190, a specific inhibitor of p38(MAPK), enhanced IL-1beta-induced LDL receptor expression, with a concomitant increase in ERK-1/2 activity.	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	13-21	mitogen-activated protein kinase 1	Homo sapiens	47-50